INTRODUCTION
studies of the fibroblast growth factor family: Apparently, heparan sulfate is required at or near the cell surface for Proteoglycans are a distinct class of glycoprotein found fibroblast growth factors to bind to and activate their receptor widely on cell surfaces and in extracellular matrices. Heparan protein tyrosine kinases (Rapraeger et al., 1991; , sulfate proteoglycans are present on the surfaces of nearly 1991). More recently, experiments have suggested a similar all adherent cells, where they bind a number of ''heparinrequirement for cell surface heparan sulfate in signaling mebinding'' proteins, including growth factors, extracellular diated by heparin-binding epidermal growth factor (Aviezer matrix molecules, cell-cell adhesion molecules, and moleand Yayon, 1994), hepatocyte growth factor (Zioncheck et cules involved in several degradative pathways (Jackson et al., 1995) , and Wnts (Reichsman et al., 1996 (Reichsman et al., ). al., 1991 . It has been proposed that heparan Cell surface heparan sulfate is carried predominantly by sulfate proteoglycans function as ''coreceptors'' for these proteoglycans belonging to two gene families: the syndemolecules, facilitating their interactions with more convencans, which are transmembrane proteins (Saunders et al., tional cell surface receptors (Bernfield et al., 1992; Schles-1989) , and the glypicans, which are glycosylphosphatidylisinger et al., 1995) . Strong support for this model comes from nositol (GPI)-anchored (David et al., 1990) . Little is known about functional differences among family members, or even about functional differences between syndecans and a pattern of 14 cysteine residues, at least some of which are H29705-30R, 5-GAGCCGCAATCTGATATC-3; and H29705- involved in disulfide bonds that help maintain the polypep-15R, 5-TCTCTCCTCCATCTT-3) were used in 5 RACE (5 tide in a compact, folded state (Herndon and Lander, 1990) .
RACE System, Life Technologies, Gaithersburg, MD), from human
In vertebrates, four glypican family members have so far 13-week fetal brain RNA, to isolate nucleotides 1-309 of human been characterized: glypican-1 (glypican) (David et al., glypican-5 (GenBank Accession No. AF001462). 1990), glypican-2 (cerebroglycan) , glypi-A partial murine glypican-5 cDNA probe was isolated by RTcan-3 (OCI-5) (Filmus et al., 1988 (Filmus et al., , 1995 , and glypican-4 PCR followed by sequential PCR with nested primers on one end (K-glypican) (Watanabe et al., 1995) . Recently, these were of the fragment. First-strand cDNA synthesis was carried out on 1 joined by a Drosophila homolog, the product of the dally mg newborn mouse brain RNA using a degenerate primer H29705-1055DR: 5-TC(C/T)TC(A/C/G/T)CC(A/G)TTCCA(A/G)CA-3.
gene (Nakato et al., 1995) .
This first strand reaction was subjected to primary PCR with degen-
The effects of mutations in both the dally gene, and in erate primers H29705-1055DR, and H29705-646D: 5-GA(A/G) the human gene for glypican-3, strongly suggest that at least (C/T)TTAA(C/T)CC(A/C/G/T)CA(C/T)TGG-3. A band correspondsome glypicans function in cellular growth control and moring to approximately 410 bp was purified by agarose gel electrophorephogenesis. Deletion of human glypican-3 results in presis from a complex mixture, and subjected to secondary PCR using and postnatal tissue overgrowth, increased risk of emprimer H29705-1055DR and primer H29705-705: 5-GCATGGAACbryonal tumors during early childhood, and numerous vis-ATACGACATTGG-3. The resulting 351-bp cDNA fragment (Genceral and skeletal anomalies (Pilia et al., 1996) . Loss of dally Bank Accession No. AF001463), encoding the partial murine glypifunction in Drosophila leads to abnormalities in certain can-5 amino acid sequence as shown in Fig. 1 , was subcloned into patterned cell divisions (Nakato et al., 1995) . Genetic interBluescript (SK 0 ) (Stratagene, La Jolla, CA) to yield pMuGlyp5. Gel-purified cDNA fragments were subcloned into either pPCRactions between dally and decapentaplegic (dpp) point to a Script or pBluescript (SK 0 ) (Stratagene) and inserts were sequenced role for glypicans in aiding signaling mediated by growth by the dideoxy chain termination method using a modified T7 factors of the dpp/bone morphogenetic protein (BMP) sub-DNA polymerase (Sequenase, United States Biochemical, Clevegroup of the transforming growth factor-b superfamily land, OH) and denatured, double-stranded template. Both T7 and (Jackson et al., 1997) .
T3 primers, as well as custom synthesized primers, were used for
In an attempt to further understand the structural and sequencing. Compression sequencing artifacts were resolved by the potential functional diversity of the glypican gene family, use of both dGTP and dITP.
we sought to identify additional vertebrate homologues. The current explosion of partial cDNA sequences available in the expressed sequence-tagged databases (dbEST) has pro- a new proteoglycan, which we have named glypican-5 the BamHI and NotI sites of pcDNA3 (Invitrogen, San Diego, CA). A cDNA for human glypican-5, deleted for its putative signal pep- (Saunders et al., 1996) , that shows all the structural features tide, was created by combining the EcoRV-BstY1 fragment of clone characteristic of glypicans, and is most closely related to 52758 and a HindIII/NotI-EcoRV PCR fragment generated using glypican-3. Veuglers and colleagues, using the same strategy primers EXP-F, 5-CCCAAGCTTGCGGCCGCAGACCTACGAas ours, also recently identified this novel member of the glypican gene family (Veugelers et al., 1997) . We report here localizes to chromosomal region 13q31-32, deletion of COS-7 cells were transiently transfected with pSP-6His-glypican-5 or control plasmid (pSP-6His) using lipofectamine (Life Techwhich is associated with 13q0 syndrome, a developmental nologies) and Optimem (Life Technologies) reduced serum media, disorder with a pattern of defects that shows significant following manufacturer's instructions. Twenty-four hours after overlap with the pattern of glypican-5 expression. transfection, the medium was replaced with DMEM (Life Technologies) containing 10% FCS and the cells were cultured for an additional 48 hr. Conditioned medium from four 100-mm plates was
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MATERIALS AND METHODS
collected for each transfection and made 6 M in guanidinium chloride, 10 mM in 2-mercaptoethanol, and 50 mM in Tris-HCl, pH cDNA Cloning and Analysis 8.0, and bound batchwise to 200 ml of preequilibrated Ni-NTA resin (Qiagen, Santa Clarita, CA) overnight at 4ЊC. Resin was transferred cDNA clones 52758, 52759, and 23723 were obtained (Research Genetics, Huntsville, AL) and sequenced as described below. A to Poly-Prep columns (Bio-Rad, Hercules, CA) and washed with 25 ml of 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 6 M guanidinium series of nested PCR primers based on sequences derived from clone chloride, 10 mM 2-mercaptoethanol followed by 25 ml 50 mM (Fisher Biotech, Pittsburgh, PA) which were stored at 080ЊC with desiccant prior to hybridization. Sections were equilibrated to room Tris-HCl, pH 8.0. The resin from each sample was divided into four equal aliquots and briefly centrifuged, and the supernatant was temperature, fixed in 4% paraformaldehyde in PBS at room temperature for 20 min, rinsed twice in PBS with 0.1 M glycine and once discarded. The aliquots of resin were each resuspended in 50 ml of digestion buffer (50 mM Tris-HCl, 15 mM phosphoric acid (pH in PBS, acetylated in 0.1 M triethanolamine (pH 8.0) and 0.25% acetic anhydride for 10 min, rinsed twice more in PBS, and then 7.1), 1 mg/ml pepstatin, 1 mM PMSF, and 250 mM NEM) containing chondroitinase ABC (0.05 U/ml) (Sigma, St. Louis, MO), heparitidehydrated through an ethanol series. Hybridization was carried out using 35 S-labeled murine glypican-5 antisense and control sense nase (4 mg/ml of enzyme prepared from flavobacterium heparinum by hydroxyapatite chromatography as described by Linker and Hov- probes, generated by in vitro transcription of plasmid pMuGlyp5, and a hybridization and posthybridization protocol as described by ingh (1972)), neither enzyme, or both enzymes together. Samples were allowed to digest for 2 hr at 37ЊC; then they were boiled in Gall et al. (1995) . Slides were dipped in Kodak NTB-2 liquid emulsion diluted 1:1 with distilled water, and exposed for 21-28 days SDS-containing sample buffer (final concentrations: 50 mM TrisHCl, pH 6.8, 2% SDS, 10% glycerol, 150 mg/ml bromphenol blue, at 080ЊC. Developed sections were stained in Hoechst 33258 (bisbenzimide) at 20 mg/ml or toluidine blue (0.005% in water). In some 50 mM dithiothreitol), separated on a 7.5% SDS-PAGE reducing gel, and electrophoretically transferred to nitrocellulose. Blots were cases, adjacent slides were also hybridized with 4EX, a probe for glypican-1 (Litwack et al., 1994) . probed with an anti-6His-specific monoclonal (Clontech, Palo Alto, CA) and enhanced chemiluminescence detection reagents (Amersham, Arlington Heights, IL).
Radiation Hybrid Mapping
The chromosomal localization of human glypican-5 was deterNorthern/Dot Blot Analysis mined by PCR screening of the 93 clones of the GeneBridge 4 radiation hybrid panel (Walter et al., 1994) (Research Genetics) . PCR was A mouse multiple tissue Northern blot (Clontech) was analyzed performed using two pairs of primers. The first pair, Gen-Glyp5-F1 for glypican-5 mRNA. This blot contains approximately 2 mg of (F1), 5-TGGAATGAAGACCACCAC-3, and Gen-Glyp5-R1 (R1), 5-poly(A) / RNA prepared from seven distinct adult BALB/c tissues, TGTCCATATTGAATTTTATTCG-3, was derived from the exon subjected to electrophoresis on a denaturing formaldehyde 1.2%
and intron sequence, respectively, that flank a splice donor site (data agarose gel, transferred to a cationic nylon membrane, and immobinot shown) following the sequence encoding amino acid residue 385 lized by UV irradiation (Sambrook et al., 1989) . The filter was hy-(identifiable in the fifth line of human glypican-5 sequence in (Feinberg and Vogelstein, 1983) , and then CCG-3, and Gen-Glyp5-R2 (R2), 5-TTGGCTTCTGGAAGTsubsequently with a b-actin cDNA probe to verify similar loading TAGTG-3, was derived from the C-terminal coding sequence and and quality of RNA in each lane.
3 untranslated region, respectively. PCR conditions were as follows: A human multiple tissue RNA blot (Human RNA Master Blot, 94ЊC for 3 min, followed by 30 cycles of 94ЊC for 1 min, 52ЊC for 1 Clontech) was also analyzed for glypican-5 mRNA. This dot blot min, and 72ЊC for 1 min, in a buffer containing 100 ng template contains normalized loadings of 100-500 ng of each poly(A) / RNA DNA, 500 nM each primer, 200 mM dNTP, 3 mM MgCl 2 , 50 mM per dot from 50 different human tissues and 6 different control KCl, 10 mM Tris-HCl, pH 9.0, and 5% DMSO in a total volume of RNAs and DNAs. The filter was hybridized in ExpressHyb solution 20 ml. Primer pair F1/R1 and F2/R2 amplified a 157-and 167-bp (Clontech) with the human glypican-5 NotI-XbaI fragment of pBSfragment, respectively, from human genomic DNA, but not from Glyp5 labeled with [a- 32 P]dCTP by random priming (Feinberg and hamster DNA. Placement of the glypican-5 locus onto the STS-based Vogelstein, 1983). Signals were detected and quantified by Phosmap of the human genome was carried out using the RHMAPPER phorImager (Molecular Dynamics, Sunnyvale, CA).
program available through the World Wide Web server of the Whitehead Institute (http://www-genome.wi.mit.edu/cgi-bin/contig/ rhmapper.pl).
In Situ Hybridization
Random-bred Swiss mice (CD-1, Charles River Laboratories) were naturally mated. The day of identification of a vaginal plug RESULTS was considered E0.5, and the day of birth was considered P0. For embryonic tissue, pregnant animals were sacrificed by cervical dis-
Cloning of Human and Murine cDNAs Encoding a
location and embryos were removed. Neonatal and early postnatal Novel Glypican Family Member animals were anesthetized by hypothermia and decapitated, and brains were immediately removed into ice-cold phosphate-buffered To identify potential new members of the glypican gene saline (PBS: 137 mM NaCl, 2.68 mM KCl, 7.83 mM Na 2 HPO 4 , 1.47 family, we performed a BLAST search of the National Center mM KH 2 PO 4 ). Nonpregnant adult animals (ú6 weeks old) were also for Biotechnology Information database of expressed sequence sacrificed by cervical dislocation and their brains were removed tags (dbEST), using the full-length amino acid sequence of into ice-cold PBS. Freshly dissected mouse embryos and postnatal the known family members as query sequences. In addition brains were embedded in OCT (Miles, Elkhart, IN) and quick frozen to identifying multiple cDNA sequences corresponding to in isopentane on dry ice, while adult brains were quick frozen murine and human clones of the known vertebrate glypicans, directly in isopentane without embedding. All samples were temwe identified five partial cDNA sequences (GenBank Accesporarily stored at 080ЊC and then equilibrated to 018ЊC, and 12-to 14-mm cryostat sections were collected on Probe-On Plus slides sion Nos. F11477, H29705, H29706, T77270, and F13387 deCopyright ᭧ 1997 by Academic Press. All rights of reproduction in any form reserved.
rived from clones designated c-2x12, 52758, 52759, 23723, potential leader sequence and GPI-attachment signal, respectively. Application of the algorithm of Nielsen et al. and c-3mf05, respectively, from a normalized human infant brain cDNA library) that represented apparently novel glypi- (1997) to the N-terminal hydrophobic stretch predicts a signal peptide with cleavage at Ser
24
, while the C-terminal can-like sequences. Three of these cDNA clones (52758, 52759, and 23723) were obtained from a commercial supplier sequence is typical of GPI-attachment signals in that a stretch of hydrophobic amino acids is preceded by a poten-(Research Genetics) and further sequenced, confirming by sequence identity that cDNA clone c-2x12 was also derived tial ''hinge,'' in this case the charged amino acid Glu 555 . Application of the v, v / 2 rule (Kodukula et al., 1993) from the same mRNA species, which we named glypican-5. Because all of these cDNA's lacked 5 sequences that could identifies two sites with equal probability for cleavage and GPI attachment: residues Gly 549 and Ala
551
. Removal of both encode amino acids homologous to the 69-75 most N-terminal amino acids of other glypicans, we cloned the 5 end of the N-and C-terminal signal sequences from glypican-5 would result in a mature protein with a molecular mass of the glypican-5 mRNA from 13-week human fetal brain RNA using rapid amplification of cDNA ends (RACE). The com-58.5 kDa. Figure 1 aligns the predicted human and partial murine posite cDNA sequence for glypican-5 is available as GenBank Accession No. AF001462.
glypican-5 protein sequence with the sequences of other members of the glypican gene family. Mature human glypiTo facilitate analysis of glypican-5 mRNA expression in mice, we also derived a murine cDNA probe. Forward can-5 is predicted to contain structural features consistent with other members of the glypican gene family, including (H29705-646D) and reverse (H29705-1055DR) degenerate PCR primers were designed based on amino acid residues the 14 cysteine residues that are conserved among all glypican family members (as well as the additional pair of cys-287-292 and 418-423, respectively, of the deduced human glypican-5 sequence. These represent sequences that have teines that is present in glypican-1, -3, and -4), in addition to five serine-glycine dipeptide sequences (Ser , and Ser
509
) that, taken in the context of neighboring amino acid sequences, are potentially consistent can family members ( Fig. 1 ). RT-PCR was performed on P0 murine brain RNA and the predicted 410-bp size range with glycosaminoglycan attachment sites (Bourdon et al., 1987; Zhang and Esko, 1994) . purified from a complex mixture. Secondary PCR amplification of this template DNA, using the same degenerate reverse primer and a nondegenerate human-specific forward
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primer (H29705-705), resulted in a single PCR fragment of Protein the predicted 351-bp size. Subcloning and sequencing of this fragment confirmed it to be murine glypican-5, with 85%
To test whether glypican-5 is indeed a proteoglycan we expressed it in COS-7 cells by transient transfection. A mamamino acid sequence identity to human glypican-5 (Fig. 1) . The partial murine glypican-5 sequence is available as Genmalian expression vector, pSP-6His-glypican-5, which encodes human glypican-5 substituted with a 6-histidine tag Bank Accession No. AF001463.
at the N-terminus of the mature protein, was devised to permit purification on Ni-NTA agarose (Janknecht et al., Sequence Analysis 1991). Conditioned media from pSP-6His-glypican-5-transfected and control-transfected cultures were subjected to NiOur composite human glypican-5 cDNA is 1938 bp in length. The sequence agrees at most positions with that NTA affinity chromatography and the bound material was treated with glycosaminoglycan lyases, followed by SDSobtained by Veuglers et al. (1997; GenBank Accession No U66033) and includes an additional 67 nt of 5 untranslated PAGE, and Western blotting with an anti-6His monoclonal antibody. No signal was detected in material isolated from sequence. We noted sequence discrepancies between U66033 and our sequence at nucleotides positions 694 and pSP-6His-glypican-5 transfectants that was untreated (Fig. 2 , lane 1), treated with chondroitinase ABC alone (Fig. 2, lane 2) , 815 of our sequence, which was surprising since we both used the identical EST cDNA clone (clone ID, 52758) to or treated with heparitinase alone (Fig. 2, lane 3) . However, combination of heparitinase and chondroitinase ABC reobtain sequence in those regions. Since these differences resulted in alternative amino acid assignments of Gly 205 sulted in the detection of a single protein band of approximately 65 kDa by reducing SDS-PAGE (Fig. 2, lane 4) In to Cys 205 and Ser 245 to Phe 245 in their and our sequences, respectively, we used synthetic sequencing primers posimaterial derived from control transfections, no bands were detected under any digestion condition (data not shown). tioned approximately 45 nt from the residues in question to unequivocally confirm that our cDNA sequence reflects
These results indicate that glypican-5 is modified with glycosaminoglycan chains, and that, at least under conditions the correct cDNA sequence of clone ID, 52758, and therefore the correct conceptual amino acid sequence for human of transient transfection in COS-7 cells (but perhaps not in other cells-see Discussion), can be a hybrid proteoglycan, glypican-5. The open reading frame predicts a 572-aminoacid polypeptide containing both an amino and carboxy terpossessing both heparan and chondroitin sulfate. Our inability to detect glypican-5 by Western blotting prior to removal minal stretch of hydrophobic residues, consistent with a Schematic alignment of glypican core proteins, revealing the high degree of structural conservation between family members. Filled boxes correspond to signal sequences, gray areas correspond to predicted mature core proteins. Black lines within the gray areas denote cysteine residues, while black lines extending up from the gray areas denote potential glycosaminoglycan attachment sites. Potential N-linked sites of glycosylation are indicated by black triangles. (C) Sequence similarities between the predicted mature core proteins of vertebrate glypicans as predicted by the GCG software Distances and the multiple sequence alignment shown in A. hGLYP-1, human glypican; rGLYP-2, rat cerebroglycan; hGLYP-3, human OCI-5; mGLYP-4, mouse K-glypican; hGLYP-5, human glypican-5; dDLY, Drosophila dally. The human and murine glypican-5 cDNA sequences are available as GenBank Accession Nos. AF001462 and AF001463, respectively. tissues, with special emphasis on regional distribution within the brain (the organ in which, in mice, the highest levels of glypican-5 mRNA had been seen). For this purpose a cDNA probe, corresponding to the full-length human glypican-5 cDNA, was hybridized to a dot blot containing poly(A) / RNA from multiple human tissues (Fig. 4) . The quantity of mRNA loaded on each spot of this membrane had been previously normalized relative to a battery of eight constitutive genes, thus allowing meaningful comparisons of mRNA levels between tissues (Spanakis, 1993; Spanakis and Brouty-Boyé , 1994) . As seen in Fig. 4 , glypican-5 message was detected widely throughout the central nervous system, including within the pituitary gland. Consistent with the data in mouse, glypican-5 mRNA was also detected in the kidney and testis. A wide range of tissues, including several abdominal visceral, cardiovascular, pulmonary, to SDS-PAGE under reducing conditions, followed by Western blotting using an anti-6His monoclonal antibody for detection. A single Ç65-kDa core protein band was detected in material from pSP-6His-glypican-5-transfected cells after enzymatic digestion with both heparitinase and chondroitinase ABC. No bands were detected in material isolated from cells transfected with a control plasmid (not shown).
of both types of glycosaminoglycans is not surprising, given the often poor transfer efficiency of large proteoglycans and the generally poor binding of intact proteoglycans to nitrocellulose membranes (Rapraeger et al., 1985) .
Expression Pattern of Glypican-5 mRNA
To investigate the tissue distribution of glypican-5 mRNA in human and murine tissues, we carried out a series of membrane (Northern and dot blot) and in situ hybridizations. Hybridization of the murine glypican-5 cDNA probe to a murine adult tissue Northern blot detected a major 3.9-kb mRNA and a minor 4.4-kb species predominantly in adult brain (Fig. 3, lane 7) . As seen in Fig. 3 , lane 2, a low The cellular localization of glypican-5 mRNA in the denation of multiple sections did not suggest any apparent gradation of hybridization along the anteroposterior or dorveloping and adult mouse was evaluated by in situ hybridization. [ 35 S]UTP-labeled, single-stranded, murine glypicansoventral axes of the limb; however, there did appear to be reduced hybridization over the chondrogenic core. Exami-5 antisense and sense control probes were hybridized to fresh frozen tissue sections from animals at E10.5, E12.5, nation of the urogenital ridge at high magnification (Figs. 5D and 5E) indicated that glypican-5 mRNA is expressed E14.5, E16.5, postnatal day 0 (P0), and at adulthood (ú6 weeks). In general, glypican-5 mRNA was found in rein the mesonephros. Hybridization was consistently weakest in the rostral nephric duct and strongest in the caudal stricted subsets of cells within a few discrete organ systems. For example, at E10.5, glypican-5 is expressed in the limb nephric duct. The latter gives rise to both the most newly generated mesonephric vesicles and ultimately the ureteric buds, urogenital ridge, ventral wall of the otic vesicle, dorsal root ganglia (DRG), parts of the maxillary process (Fig. 5) , buds of the metanephric kidney (Saxé n, 1987). At later embryonic ages, glypican-5 mRNA was found in and the most ventral surface of the midbrain tegmentum (not shown).
many of the same organ systems as were seen at E10.5, although not always in the same cellular distribution. For Glypican-5 hybridization within the limb bud was especially strong, with labeling throughout the mesenchyme example, at E14.5, glypican-5 mRNA was still found in the limb, but expression was now restricted to condensing mesbut not in the overlying ectoderm (Figs. 5A and 5B). Exami- 35 S-labeled glypican-5 probe (D) and the same section stained with toluidine blue (E). Arrowhead indicates hybridization signal in caudal nephric duct (the bright spot adjacent to the letter D is due to light scattering by a dust particle). Abbreviations: (drg) dorsal root ganglion, (lb) limb bud, (ov) otic vesicle, (me) mesonephros, (mp) maxillary process. Sections in A-D were exposed for 6 weeks and photographed using dark-field illumination. A-C are shown at the same magnification, as are D and E. Bar in C is 1 mm; in D, 300 mm.
enchyme at the distal tips of the developing digits (Fig. 6A) .
Although, at E10.5, the distribution of glypican-5 mRNA in the central nervous system was seen to be quite limited, In the urogenital system, glypican-5 mRNA was readily detected in the developing permanent kidney (metanephros) expression becomes more widespread as the nervous system matures. In the anterior telencelphalon, for example, collecat E14.5 (not shown) and E16.5 (Fig. 6C) , where it was localized to condensing mesenchymal aggregates and the epithetions of cells just dorsal and ventral to the evaginating olfactory bulb express glypican-5 by E14.5 (Fig. 6B ). More caulial tubules derived from these aggregates (Figs. 6E and 6F) . It was consistently observed that the most highly differentidally, expression was also seen in cells of the isthmus, or midbrain/hindbrain junction (Fig. 6B ). In the spinal cord, ated tubular structures, as defined by a well-formed tubular architecture containing a central lumen, lacked hybridizaglypican-5 hybridization was seen as early as E12 within two bilaterally symmetric pairs of continuous columns of tion signal. This suggested that glypican-5 mRNA expression may decline as renal tubules mature. Glypican-5 hycells extending rostrocaudally within the ventral gray matter (not shown), a pattern that could still be detected at bridization was also detected at E16.5 in another part of the urogenital system, the developing vas deferens, which is E16.5 (Fig. 6C) . Strong hybridization within the medulla was also evident at E16.5. On lateral sections of E16.5 aniderived from the mesonephric duct. mals (Fig. 6C) , little glypican-5 hybridization was seen in mus, hybridization was strongest in lateral and ventral regions (Fig. 7A) . In the more posterior regions of the midmidbrain and forebrain structures, with the exception of anterior ventral forebrain; however, on more medial sections brain, glypican-5 hybridization was widely observed within the deeper nuclei of the cerebellum, tectum, and pons. No of the same animal (Fig. 6D) , glypican-5 mRNA was found in several additional structures. For example, in the dienhybrdization to any CNS structures was seen with a control sense-strand probe (Fig. 7B) . cephalon, glypican-5 was detected in subsets of thalamic nuclei and in much of the ventral and lateral hypothalamus.
In the adult brain, glypican-5 mRNA was expressed even more widely, although at levels that appeared quite low (as The striatal primordium, or ganglionic eminence, showed little glypican-5 hybridization, except along its ventricular judged by lower signal intensity after similar autoradiographic exposure times). Figure 7 presents the pattern of border (see Discussion). Hybridization was also seen in the midbrain tectum, in the deep nuclei of the cerebellum, and expression of glypican-5 in the forebrain and contrasts it with that of glypican-1 (Fig. 7C) , a glypican that is also in parts of the pons. Other tissues expressing glypican-5 at E16.5 included the trigeminal ganglion, the pituitary, and widely expressed in the brain (Litwack et al., 1994) . Glypican-5 hybridization was seen at fairly uniform levels the cochlea of the inner ear (Fig. 6C) . Interestingly, the latter is derived specifically from the ventral wall of the otic vesithroughout the cerebral cortex, hippocampus, and diencephalon, with the exception of hippocampal areas CA1-cle (Martin and Swanson, 1993) , where glypican-5 hybridization had been detected at E10.5 (Fig. 7) .
CA2, in which pyramidal cells showed elevated levels of hybridization (Fig. 7D) . In contrast, glypican-1 is most Because of its interesting patterns of expression within the nervous system, as well as its relatively greater abunhighly expressed in hippocampal areas CA3-CA4 and in thalamus, as well as at somewhat lower levels in the dentate dance in that organ system in adult tissues (cf. Figs. 4 and 5), in situ hybridization analysis of glypican-5 expression at gyrus, hippocampal areas CA1-CA2, and cerebral cortical layers 2/3, 5 and 6 (Litwack et al., 1994) . later developmental stages was limited to the central nervous system. In comparison to the E16.5 central nervous system, P0 brain demonstrated widespread expression of
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glypican-5 mRNA throughout the forebrain (Fig. 7A) . In very anterior sections (not shown), glypican-5 mRNA was
To gain other potential clues about the biological function of glypican-5, we mapped the glypican-5 gene within detected within the subventricular zone and mitral cell layer of the olfactory bulb. Slightly more posteriorly, glypithe human genome using radiation hybrid (RH) mapping, a technique that involves scoring the presence or absence of can-5 was detected in structures of the ventral forebrain, including the preoptic nuclei and the olfactory tubercle. As a genomic marker among independent human/hamster hybrid cell clones bearing human genomic fragments produced at E16.5, the striatum was generally negative for glypican-5. Still more posteriorly, glypican-5 mRNA was detected in by X-irradiation. A pattern of amplification of PCR products is compared with the patterns contained in a database of both the hippocampus as well as the cerebral cortex. In the cerebral cortex, transcript appeared most abundant within previously mapped genomic framework markers. Among the advantages of this technique is its ability to order markthe deepest layers of the developing cortical plate. In the diencephalon, mRNA expression was detected within ers spanning millions of base pairs of DNA, at a resolution not easily obtained by other techniques. In addition, the some, but not all thalamic nuclei. In particular, hybridization was detected in the lateral geniculate, centromedian, estimated distances obtained are directly proportional to physical distance. and laterodorsal nuclei of the thalamus. In the epithalamus strong hybridization was seen primarily in the lateral, but
We utilized for these experiments the GeneBridge 4 RH panel (Walter et al., 1994) and two pairs of glypican-5-spenot the medial habenular nuclei, while in the hypothala- Asterisks indicate hybridization to regions of condensed, undifferentiated mesenchyme; arrowheads, hybridization to differentiated tubular epithelial structures; arrows, nonhybridizing well differentiated tubular epithelial and glomerular structures. A, B, and D were exposed for 3 weeks; C and E were exposed for 5 weeks. Abbreviations: (c) cochlea, (cb) deep cerebellar nuclei, (hb) hindbrain, (ht) hypothalamus, (k) kidney, (m) medulla, (mb) midbrain, (ob) olfactory bulb, (p) pons, (pi) pituitary, (s) spinal cord, (te) telencephalon, (tec) midbrain tectum, (tg) trigeminal ganglion, (th) thalamus. Bar: A, 300 mM; B, 1 mm; C, 2 mm; D, 1 mm; E, 300 mm. Apparent hybridization to the dorsal aorta and to some skeletal elements in the section shown in C was considered to be nonspecific because similar patterns were seen using control probes. In addition, consistent hybridization to these elements was not seen in all experiments. S-labeled murine glypican-5 antisense probe (A,C), sense control probe (B), or an antisense probe for glypican-1 (D). A and B were exposed for 6 weeks; C and D were exposed for 5 weeks. Abbreviations: (a) amygdala, (CA1 and CA3) pyramidal cell layers of hippocampal cortex, (ctx) cerebral cortex, (dg) dentate gyrus, (hi) hippocampal cortex, (lh) lateral hypothalamus, (th) dorsal thalamus. Bar, 1 mm. cific PCR primers. One pair spanned the C-terminus to 3 (Fig. 8) . As seen in Fig. 8 , the genomic framework markers surrounding this region of the glypican-5 gene correspond untranslated region and the other spanned a splice donor site located following nucleotide residue 1235 (GenBank to the region characterized cytogenetically as bands q31-32, consistent with the localization of the glypican-5 gene to Accession No. AF001462) that was identified serendipitously by 3 RACE of an unspliced glypican-5 mRNA (data 13q32 via fluorescence in situ hybridization (Veugelers et al., 1997) . While no genetic syndrome has been mapped not shown). These primer pairs were preselected and evaluated for specificity (ability to amplify a single band from specifically to this discrete locus, as discussed below, a number of human patients have been characterized with human, but not hamster, genomic DNA). Data were submitted for analysis via computer to the Whitehead-MIT chromosomal deletions, of various sizes that would include the glypican-5 gene. These patients display a phenotype reCenter for Genome Research which is creating an integrated map of the human genome based on the GeneBridge RH ferred to as 13q0 syndrome which includes a number of developmental abnormalities. panel (Hudson, 1995) . The results localized the glypican-5 genomic markers to human chromosome 13. Specifically, the marker spanning the exon-intron boundary at nucleotide residue 1235 of the human cDNA mapped 1.51 cR DISCUSSION telomeric to the framework marker CHLC.GATA73H01, while the genomic marker from the C-terminus and 3UTR
The experiments described above characterize the structure and expression of a fifth member of the glypican family mapped 1.61 cR telomeric to framework marker WI- 9265 FIG. 8 . Localization of the human glypican-5 gene to the chromosome 13 radiation hybrid and cytogenetic maps. On the left the chromosome 13 radiation hybrid map positions of two glypican-5 exons, which include amino acid residues 352-384, and the glypican-5 C-terminus, respectively, are shown. On the right the correspondence of this region of the radiation hybrid map to cytogenetic bands q31-32 is shown.
of cell surface proteoglycans. Glypican-5 has a structure tachment sites (Bourdon et al., 1987) , including those that are specifically modified with heparan sulfate (Zhang et al., typical of other glypicans (Fig. 1) , is modified with glycosaminoglycan side chains, at least when expressed in vitro 1995). The remaining serine-glycine pairs, at Ser 441 and in particular Ser
495
, also have neighboring acidic residues (Fig. 2) , and, like other glypicans, is expressed in a highly tissue-specific manner during embryogenesis (Figs. 3-7) .
within 6 amino acids and might represent glycosaminoglycan attachment sites as well (Zhang et al., 1995) .
Results of transient expression in COS-7 cells (Fig. 2) sup-
Glycosaminoglycan Modification of Glypican-5
port the notion that at least two sites in glypican-5 are substituted with glycosaminoglycans, since both heparitiFive serine-glycine dipeptides, representing potential glycosaminoglycan attachment sites, are present in the denase and chondroitinase ABC were required to degrade the intact proteoglycan to its core protein. Although cell surface duced amino acid sequence of glypican-5. As in other glypicans, these dipeptides are clustered near the carboxy termiproteoglycans of the syndecan family frequently contain both heparan sulfate (HS) and chondroitin sulfate (CS), nus. Three of them, Ser , occur as SGSG or SGXG sequences in close proximity to acidic residues, members of the glypican family have been reported to bear only HS (Steinfeld et al., 1996) , even when isolated from features particularly characteristic of glycosaminoglycan at-cells whose syndecans are clearly hybrid (bearing both CS groups, within this C-terminal region, reveal similarities of only 8-18%. and HS) (Shworak et al., 1994a) . Although glypican-5 may differ from other glypicans in this respect, it is also possible It is interesting to contrast this organization with that described for the syndecans, the other major family of cell that the pattern of glycanation seen in the present study was a consequence of overexpressing this molecule in COSsurface proteoglycans. Although syndecans are transmembrane proteins, their extracellular domains are notable for 7 cells, by transient expression, and not indicative of the pattern normally found in vivo. Interestingly, when Veua high content of serine, threonine and proline, an absence of cysteine, and extremely poor sequence conservation exglers et al. (1997) expressed glypican-5 in K5652 cells by stable transfection, only heparan sulfate chains were found. cept in the immediate vicinity of glycosaminoglycan attachment sites (Bernfield et al., 1992) . Clearly, the syndeThe apparent molecular weight of COS-7 cell-synthesized glypican-5, following removal of glycosaminoglycan chains, cans have much in common with the short C-terminal domain of the glypicans, but little in common with the Nwas approximately 65 kDa when analyzed by SDS-PAGE under reducing conditions. This is larger than the 58.5-kDa terminal domain. Yet it is the N-terminal domain of glypicans that has been most highly conserved by evolution, calculated mass of the core protein (with signal peptides removed), and suggests possible posttranslational modifiraising the strong possibility that this domain mediates some function unique to the glypicans. It is tempting to cation at the three potential N-linked glycosylation sites predicted from the cDNA sequence.
speculate that this domain is involved in the direct interaction of glypicans with as yet unknown extracellular ligands. Indeed, several cases have been described where proteoglycans are known to specifically bind other molecules via
Relationship of Glypican-5 to Other Cell Surface
protein-protein, rather than glycosaminoglycan-protein,
Proteoglycans
interactions (Cheifetz and Massague, 1989; Krusius and Ruoslahti, 1986; Vogel et al., 1984) . Comparison of the amino acid sequences of the known vertebrate glypicans suggests greater relatedness between some family members than others. Using the alignment of Developmental Regulation of Glypican-5 mRNA glypican-1 through -5 shown in Fig. 1A (with N-and C-
Expression in the Mouse Embryo
terminal signal peptides removed), and the Distances software package from Genetics Computer Group, we find 46-In the E10.5 embryo, the earliest stage examined, glypican-5 mRNA was found abundantly throughout the rela-52% similarity among human glypican-1, rat glypican-2, and mouse glypican-4, and 50% similarity between human tively undifferentiated, proliferative mesenchyme of the developing limb bud. As these cells begin to differentiate into glypican-5 and -3. In contrast, comparisons between members of these two groups reveal similarities of only 25-29%, skeletal and connective tissue elements, glypican-5 mRNA becomes restricted to mesenchymal cells at the distal tip suggesting these groups form distinct subfamilies (Fig. 1C) .
Close inspection of the sequences of glypican family of the limb. For example, by E12.5 glypican-5 mRNA expression is restricted to the prechondrogenic mesenchyme members suggests that these proteins may be divisible into two domains: About 85% of the amino acids in each glypiat the distal tips of the forming digits. Thus, in both cases, glypican-5 is localized to highly proliferative cells that are can comprise a large N-terminal domain in which all 14 of the invariant cysteines reside, but in which, to the extent in the process of generating differentiated structures. Glypican-5 mRNA was also detected in E10.5 mesonephtested so far, no glycosaminoglycan chains are found (Mertens et al., 1996, and unpublished observations) . Following ros, in association with the caudal nephric duct. The nephric duct gives rise to the bilateral ureteric buds which, in that is a C-terminal domain containing glycosaminoglycan attachment sites (clustered serine-glycine dipeptides turn, induce proliferation and condensation of metanephric mesenchyme into pretubular aggregates. At later stages, flanked by acidic residues), a single pair of cysteine residues in some, but not all, glypicans, and finally a short region, clear association of glypican-5 mRNA with these pretubular aggregates, as well as with the differentiating tubular epilacking cysteines but relatively enriched in serine, threonine, proline, and/or basic amino acids, that provides a linkthelial cells recently derived from these aggregates, could readily be seen. In contrast, more highly differentiated tuage to the GPI anchor. Interestingly, most of the strong sequence conservation among glypicans is confined to the bules and glomeruli failed to express glypican-5 mRNA. This pattern of expression contrasts with that of both glypi-N-terminal domain. For example, within this region, glypican-1 and -4 are 54% similar, and glypican-3 and -5 are can-4 (K-glypican) and glypican-1. Glypican-4 mRNA is expressed relatively late in kidney development where it is also 54% similar. Within the C-terminal domain, sequence conservation is mainly confined to the immediate vicinity detected in some pretubular aggregates, but is found mainly in the most differentiated tubules. Expression in tubules of the serine-glycine dipeptides, with very little similarity seen elsewhere. For example, within this region, glypicanpersists at later times, but little expression is found in glomeruli (Watanabe et al., 1995) . By comparison, glypican-1 1 and -4 are 38% similar, whereas glypican-3 and -5 are only 25% similar. Comparisons between members of these two mRNA appears to be expressed strongly in newly formed
Copyright ᭧ 1997 by Academic Press. All rights of reproduction in any form reserved. glomerular structures (S. Paine-Saunders and A. D. Lander, seen with other glypicans. Glypican-2 is expressed by developing neurons almost as soon as they become postmitotic, unpublished data).
Kidney development is a complex process that is thought but then rapidly disappears (Ivins et al., 1997; Stipp et al., 1994) . Glypican-1 mRNA seems to appear in post-mitotic to require multiple soluble factors to drive both induction of tubules and branching of the ureteric bud (Hammerman, neurons slightly later than glypican-2 (at least in the cerebral cortex (E. D. Litwack and A. D. Lander, unpublished 1995; Hammerman et al., 1992) . Interestingly, both in vitro and in vivo experiments have implicated heparan sulfate-dedata)), but reaches its highest level of expression in the adult brain (Litwack et al., 1994) . These data suggest that, in some pendent growth factors, including FGFs and Wnts, in these events (Herzlinger et al., 1994; Perantoni et al., 1995;  Stark developing neurons at least, expression of glypicans may progress from predominantly glypican-2, to predominantly et al., 1994) . A recent in vitro study has also demonstrated a requirement for heparan sulfate itself in branching morphoglypican-5, to predominantly glypican-1. The significance of such alternation between glypican family members is genesis of the ureteric bud, and in controlling the expression of wnt-11 (Kispert et al., 1996) . The highly restricted and unclear, and is likely to remain so until the relevant ligands of individual glypicans in the nervous system are better dynamic patterns of expression of different glypicans raise the possibility that these proteoglycans may play as yet undefined understood. To this end, it is interesting to note that many of the heparin-binding growth factors that are candidates for roles in coordinating the many growth factor-driven morphogenetic events that underlie kidney development.
interacting with glypicans in regions such as the developing limb and kidney (e.g., fibroblast growth factors, wnts, transAlthough expression of glypican-5 mRNA in both the developing kidney and limb correlates with the locations forming growth factor-b, bone morphogenetic proteins) are also believed to regulate the differentiation and behavior of of highly proliferative cells, the pattern of glypican-5 expression in the nervous system clearly points to functions unrepostmitotic neurons (Chalazonitis et al., 1995; Fradkin et al., 1995; Iwasaki et al., 1996; McFarlane et al., 1995;  Unlated to proliferation. Most tellingly, the cell layers of the central nervous system in which most neural proliferation sicker et al., 1996) . is confined (the early neuroepithelium and later ventricular zones) are conspicuously lacking in glypican-5 expression Deletion of the Glypican-5 Gene May Be throughout the brain, with the sole exception of the striatal Associated with Some Phenotypic Features primordium (Fig. 6D) . In contrast, ventricular zones show of the Human 13q0 Syndrome strong hybridization for glypican-1 throughout the brain and E. D. Litwack and A. D. Lander, unpub- Using radiation hybrid mapping we localized the human glypican-5 gene to a region of the long arm of chromosome lished data) and for glypican-4 in parts of the telencephalon (Watanabe et al., 1995) .
13 defined cytogenetically as 13q31-32; these data are consistent with the mapping of human glypican-5 to 13q32 by In general, glypican-5 expression in the early nervous system marks distinct subsets of newly generated postmitotic fluorescence in situ hybridization (Veugelers et al., 1997) .
Interstitial deletions involving this region of the human neurons, such as dorsal root ganglia and columns of presumptive primary motoneurons in the ventral spinal cord genome are associated with a constellation of developmental abnormalities known collectively as 13q0 syn-(Figs. 5 and 6). In some cases, glypican-5 expression also demarcates morphological boundaries, such as the middrome. The phenotype of individual patients is variable, owing likely to the variable size of the specific interstitial brain-hindbrain junction, or isthmus, and the dorsal and ventral surfaces of the evaginating olfactory bulb (Fig. 6B) .
deletions involved as well as other possible genetic modifiers. However, phenotypic features associated with interstiOnly in later embryonic and perinatal life does glypican-5 begin to be widely expressed throughout the brain. At these tial deletions involving 13q31-32 include severe intrauterine growth retardation; functional as well as structural abstages, relative positions of cells can sometimes be used as indicators of stage of differentiation. For example, in the normalities of the nervous system including mental retardation, hypotonia, microcephaly, encephalocele, holodeveloping cerebral cortex, the oldest postmitotic neurons lie in the deep portion of the cortical plate, while the most prosencephaly, partial anencephaly, agenesis of the corpus callosum, and deafness; developmental abnormalities of recently generated are located more superficially. Preferential expression of glypican-5 in the deep cortical plate (Fig. other organ systems including hypoplastic kidneys, hypoplastic ureters, hypoplastic adrenals, ambiguous genitalia, 7A) strongly suggests that glypican-5 is not expressed by neurons as soon as they become postmitotic, but rather it imperforate anus; and skeletal abnormalities primarily including absent or hypoplastic thumbs and metacarpal/metaappears somewhat later. Similarly, the relatively low glypican-5 in situ hybridization signals that are seen over inditarsal bones of the extremities (Brown et al., 1993 (Brown et al., , 1995 . Brown and colleagues have identified a correlation between vidual neurons in the adult brain (Figs. 7C and 7D) suggest that, in expressing cells, glypican-5 mRNA levels decline the major phenotypic features of this disorder and interstitial deletions encompassing portions of 13q32, suggesting significantly with cell maturation.
These dynamic changes in glypican-5 expression are quite the location of gene(s) in this region responsible for 13q0 syndrome (Brown et al., 1993 (Brown et al., , 1995 . different from, and in some senses complementary to, those
